Selected article for: "action possible mode and possible mode"
Author: Regidor, Pedro-Antonio; Santos, Fernando Gonzalez; Rizo, Jose Miguel; Egea, Fernando Moreno
Title: Pro resolving inflammatory effects of the lipid mediators of Omega 3 fatty acids and its implication in SARS COVID-19
  • Cord-id: eid7ng1t
  • Document date: 2020_10_8
    • ID: eid7ng1t
    Snippet: COVID-19 is a new disease caused by coronavirus SARS-CoV-2. It was first described in 2019, developed into an epidemic in January 2020 and has spread the global to the present COVID-19 pandemic. Specialized pro‑resolving mediators (SPMs) may play a new role in the management of this lung disease because SPM actively stimulate the resolution of infectious inflammation and are organ protective in animal disease models. Many tissues have been suitable targets for treating inflammation with SPMs o
    Document: COVID-19 is a new disease caused by coronavirus SARS-CoV-2. It was first described in 2019, developed into an epidemic in January 2020 and has spread the global to the present COVID-19 pandemic. Specialized pro‑resolving mediators (SPMs) may play a new role in the management of this lung disease because SPM actively stimulate the resolution of infectious inflammation and are organ protective in animal disease models. Many tissues have been suitable targets for treating inflammation with SPMs or their active precursors 18-HEPE, 17-HDHA and the 14-HDHA, in order to elicit dynamic resolution of inflammation. Here we discuss the possible mode of action of these substances in the management of SARS Covid 19.

    Search related documents:
    Co phrase search for related documents
    • activate neutrophil and lung function: 1
    • active inflammation and acute ards respiratory distress syndrome: 1, 2
    • active inflammation and acute inflammation: 1, 2, 3
    • active inflammation and acute phase: 1, 2
    • active inflammation and lung disease: 1, 2, 3
    • active inflammation and lung function: 1, 2, 3
    • active inflammation and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active inflammation and lung result: 1
    • active inflammation and macrophage phagocytosis: 1
    • active inflammation resolution and acute ards respiratory distress syndrome: 1
    • active inflammation resolution and acute inflammation: 1
    • active inflammation resolution and lung inflammation: 1
    • active inflammation resolution and macrophage phagocytosis: 1